News & Events May

New Hires & Promotions

May 29, 2020

CTI welcomes all the new employees who have recently joined the team, and congratulates the employees who have recently received a promotion! Zhanna Andrushchenko joins as Senior Statistical Programmer Daniela Carvalho moves to new role as Clinical Data Associate II Evelyn Currie joins as Senior Clinical Data Associate Dana ...

Read More

Recognizing the Regulatory Agencies Supporting the Fight Against COVID-19

May 28, 2020

The COVID-19 pandemic has spotlighted the courageous work of health care workers, first responders, delivery people, grocery store clerks and stockers, and others in the supply chain providing care, food, and medical supplies ...

Read More

CTI Announces Anna McBride to Oversee Global Clinical Monitoring Department

May 27, 2020

FOR IMMEDIATE RELEASE [Covington, KY ~ May 27, 2020] CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces the addition of Anna McBride to the CTI team in the role of Vice President, Global Clinical ...

Read More

CTI Partners with St. Elizabeth Healthcare and Pulmotect to Open First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19

May 18, 2020

FOR IMMEDIATE RELEASE [Covington, KY / Edgewood, KY ~ May 18, 2020] – St. Elizabeth Healthcare has been selected as the first site of the FDA-approved Phase-2 COVID-19 clinical trial studying the drug PUL-042 of Pulmotect, Inc., in partnership with CTI ...

Read More

CTI Partners with Pulmotect on Two Phase-2 Trials Targeting COVID-19

May 11, 2020

FOR IMMEDIATE RELEASE [Covington, KY ~ May 11, 2020] – CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, is partnering with Pulmotect, Inc., a clinical-stage biotechnology company, on two COVID-19 phase 2 clinical trials ...

Read More

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

May 7, 2020

First Phase III pivotal study for an anti-GM-CSF therapy in COVID-19 patients First patient dosed in US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product ...

Read More

Subscribe to our mailing list

* indicates required